All News

FDA grants lunsotogene parvec-cwha approval for OTOF-related hearing loss, delivering single-dose gene therapy gains and expanding access with free US supply.

Off-the-shelf cema-cel clears MRD at more than triple the rate of observation alone—and may propel a shift to frontline use of CAR T-cell therapy when relapse is hard to detect.

The DEA's 30th biannual collection event arrives April 25, 2026—here's what patients and clinicians need to know.

The FDA approved dupilumab for children aged 2 to 11 years with uncontrolled CSU—the first biologic for this pediatric population.

Nicole A. Caffiero, PharmD, MBA, BCACP, concluded AMCP 2026 by highlighting key themes shaping the specialty drug market.

Parth Desai, MBBS, MD, discusses how clinicians balance liquid biopsy, tissue testing, and fast-start chemo to personalize non–small cell lung cancer treatment.

Cemdisiran offers lower treatment burden for patients living with generalized myasthenia gravis, only needing to be taken every 3 months.

An analysis shows accelerated declines in processing speed, memory, and global cognition years before incident cardiovascular disease.

The Merit-Based Incentive Payment System (MIPS) measure excluded nearly half of all patients undergoing surgery, which could affect surgeon performance.

Teplizumab-mzwv is the first disease-modifying therapy available for children as young as 1 year diagnosed with presymptomatic type 1 diabetes.

OUD diagnoses have declined, but use of medication to treat OUD has increased among Medicaid beneficiaries, highlighting policy gains and ongoing state-level disparities.

988 Lifeline rollout linked to 11% drop in youth suicide deaths, with greater reductions in states with higher call uptake, study finds.

PFAS exposure, especially PFDA, was linked to higher nonmelanoma skin cancer odds, with stronger effects observed in older adults.

There was comparable 12-month fitness and functional outcomes in lymphoma survivors, suggesting a scalable option to expand access to cardio-oncology care.

Young-onset CRC mortality rose over 3 decades in the US, largely among adults with lower educational attainment, widening socioeconomic gaps.

A new AHIP report outlines evidence-based strategies to cut chronic disease prevalence by 10% by 2035.

The 5-year prediction of MS progression, defined by clinical and objective measurements, was possible with 2 machine learning tools.

Black Maternal Health Week spotlights disparities, Medicaid postpartum coverage gains, and ongoing policy efforts to reduce maternal mortality.

Subgroup data show no reduction in cardiovascular death or myocardial infarction—and a potential signal of harm—in highly frail patients.

Clinical trials are evolving toward decentralized, patient-centered models, but enrollment challenges, outdated protocols, and infrastructure gaps persist.

Public health must be grounded in empathy, cultural competence, psychological insight, and political awareness, emphasizes Perry N. Halkitis, PhD, MD, MPH.

Tuan Vu, MD, explains the results of the NIMBLE trial, whose results will be presented at the American Academy of Neurology conference.

Food insecurity remains among children above SNAP limits, highlighting broad-based categorical eligibility gaps that exclude at-risk families just over eligibility thresholds.

DELTA 3 trial extension data show sustained improvements in disease-specific, dermatology-specific, and overall quality-of-life measures.

SPIRIT-HF reported neutral outcomes for spironolactone in HFpEF/HFmrEF, but ongoing analyses may clarify which patients benefit most.

A new study finds that highly lethal cancers receive less research support than lower-risk cancers.

LaShawn McIver, MD, MPH, discusses a new report from a task force aiming to cut chronic disease prevalence 10% by 2035 through prevention and coordinated care.

A new review explains how new therapies and technologies are guiding the treatment of acute myeloid leukemia (AML).